Prognostic markers for urothelial cancer: Obstacles and opportunities

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 4, 2012, Pages 516-517

  Malmström, Per Uno ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; BLADDER CANCER; CANCER DIAGNOSIS; CANCER PROGNOSIS; COST; EDITORIAL; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL; REPRODUCIBILITY; UROGENITAL TRACT CANCER;

FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84863004331     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.04.007     Document Type: Editorial

References (17)

1. Gårdmark T., Bladström A., Hellsten S., et al. Analysis of clinical characteristics, management, and survival of patients with Ta T1 bladder tumors in Sweden between 1997 and 2001. Scand J Urol Nephrol 2006, 40:276-282. Members of the Swedish National Bladder Cancer Registry.
2. Whelan P. Survival from bladder cancer in England and Wales up to 2001. Br J Cancer 2008, 99(Suppl 1):S90.
3. http://www.cancer.gov/aboutnci/servingpeople/snapshots/bladder.pdf.
4. Malats N., Bustos A., Nascimento C.M., et al. P53 as a prognostic marker for bladder cancer: A meta-analysis and review. Lancet Oncol 2005, 6:678-686.
5. McShane L.M., Altman D.G., Sauerbrei W., et al. Reporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2005, 2:416-422. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.
6. Dalbagni G., Kaag M., Cronin A., et al. Variability of treatment selection among surgeons for patients with cT1 urothelial carcinoma. BJU Int 2010, 106:1502-1507.
7. Brausi M., Collette L., Kurth K., et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies. Eur Urol 2002, 41:523-531. EORTC Genito-Urinary Tract Cancer Collaborative Group.
8. Herr H.W., Faulkner J.R., Grossman H.B., et al. Surgical factors influence bladder cancer outcomes: A cooperative group report. J Clin Oncol 2004, 22:2781-2789.
9. Herr H.W., Faulkner J.R., Grossman H.B., et al. Pathologic evaluation of radical cystectomy specimens: A cooperative group report. Cancer 2004, 100:2470-2475.
10. Sharkey F.E., Sarosdy M.F. The significance of central pathology review in clinical studies of transitional cell carcinoma in situ. J Urol 1997, 157:68-70.
11. Sherif A., Holmberg L., Rintala E., et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: A combined analysis of two Nordic studies. Eur Urol 2004, 45:297-303. Nordic Urothelial Cancer Group.
12. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomized controlled trial. Lancet 1999, 354:533-540. International collaboration of trialists.
13. Hussain M.H., Wood D.P., Bajorin D.F., et al. Bladder cancer: Narrowing the gap between evidence and practice. J Clin Oncol 2009, 27:5680-5684.
14. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2,596 patients from 7 EORTC trials. Eur Urol 2006, 49:466-475.
15. Zaak D., Burger M., Otto W., et al. Predicting individual outcomes after radical cystectomy: An external validation of current nomograms. BJU Int 2010, 106:342-348.
16. Accessed March 24, 2011. http://uromol.eu/.
17. Marsh S., Paul J., King C.R., et al. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish Randomized Trial in Ovarian Cancer. J Clin Oncol 2007, 25:4528-4535.